Imaxio, a Lyon, and Saint Beauzire, France-based biopharmaceutical company specialized in the areas of vaccines and genomics, has finalized a €2.9m funding round from its majority shareholder Pradeyrol Developpement.
The company intends to use the funding for clinical development of its IMX313 carrier protein platform for vaccines, and update of the marketing authorization application it filed in France for its vaccine against leptospirosis with a view to commercializing it internationally.
Led by managing director Alexandre Le Vert, Imaxio – to support its development – also relies on numerous institutional and academic partners, such as the Jenner Institute at Oxford University, Pierre Fabre, the U.S. Department of Agriculture (USDA), the French national influenza research center, and research teams working for Inserm (the French National Institute of Health and Medical Research) and the CNRS (France’s National Scientific Research Center) in Lyon, Clermont-Ferrand, Tours, Toulouse and Paris.
The company currently has 24 employees, ten of whom are engaged in R&D. In 2011 it delivered a turnover of EUR 2.4m.